trans-3,5-dimethylcinnamic acid | 67688-87-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: trans-3,5-dimethylcinnamic acid
• 英文别名: 3.5-dimethyl-trans-cinnamic acid；3.5-Dimethyl-trans-zimtsaeure；trans-3-(3,5-dimethyl-phenyl)-acrylic acid；3-(3,5-Dimethylphenyl)-prop-2-enoic acid；3-(3,5-Dimethylphenyl)prop-2-enoic acid；(E)-3-(3,5-dimethylphenyl)prop-2-enoic acid
• CAS: 67688-87-3
• 化学式: C₁₁H₁₂O₂
• 分子量: 176.215
• InChiKey: KNCJKIAOBVEDSY-ONEGZZNKSA-N

物化性质

• 沸点：
  312.4±11.0 °C(Predicted)
• 密度：
  1.118±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  trans-3,5-dimethylcinnamic acid 以70%的产率得到trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-(3,5-dimethyl-phenyl)-acrylamide
  参考文献：
  名称：

  Non-peptidic NPY Y2 receptor inhibitors

  摘要：

  该发明提供了一种新型的非肽类NPY Y2受体抑制剂，可用于治疗或预防：焦虑障碍或抑郁症；受损的哺乳动物神经组织；通过给予神经营养因子进行治疗的疾病；神经系统疾病；骨质流失；物质相关障碍；肥胖症；或肥胖相关疾病。该发明的化合物还可用于调节内分泌功能，特别是由垂体和下丘脑控制的内分泌功能，因此对于治疗或预防排卵障碍和不孕症也是有用的。

  公开号：

  US20050070534A1
• 作为产物：
  描述：

  2-(3,5-dimethylbenzyl)malonic acid 在 乙醚 、 溴 作用下， 生成 trans-3,5-dimethylcinnamic acid
  参考文献：
  名称：

  v. Braun; Nelles, Chemische Berichte, 1933, vol. 66, p. 1464,1467

  摘要：

  DOI：

文献信息

• Magnetic polymer nanocomposite-supported Pd: an efficient and reusable catalyst for the Heck and Suzuki reactions in water
  作者：Dongfang Wang、Wendong Liu、Fengling Bian、Wei Yu

  DOI：10.1039/c4nj01581a

  日期：——

  Fe3O4@undecylenic acid. Pd2+ was then immobilized on this magnetic nanocomposite to form the magnetic Fe3O4@PUVS-Pd catalyst. This catalyst exhibited excellent catalytic activity for the Heck and Suzuki coupling reactions in water, and could be simply separated by using a permanent magnet. The supported catalyst could be used consecutively for six runs without significant loss of catalytic activity.

  一种新的类型的磁响应聚合物纳米复合材料的铁3 ö 4 @poly（十一酸共-4-乙烯基吡啶共-sodium丙烯酸酯）（铁3 ö 4 @PUVS）通过4-乙烯基吡啶的自由基聚合来合成（4-VP）与丙烯酸钠（SAA）和Fe 3 O 4十一碳烯酸。然后将Pd 2+固定在该磁性纳米复合材料上以形成磁性Fe 3 O 4@ PUVS-Pd催化剂。该催化剂对水中的Heck和Suzuki偶联反应表现出出色的催化活性，可以通过使用永磁体简单地分离。负载的催化剂可连续使用六次，而催化活性没有明显损失。
• NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS
  申请人：Carruthers Nicholas I.

  公开号：US20080132540A1

  公开（公告）日：2008-06-05

  The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

  本发明提供了新型的非肽类NPY Y2受体抑制剂，可用于治疗或预防：焦虑症或抑郁症；受损哺乳动物神经组织；通过给予神经营养因子治疗的疾病；神经系统疾病；骨质流失；物质相关疾病；肥胖症；或肥胖相关疾病。本发明的化合物也可用于调节内分泌功能，特别是由垂体和下丘脑控制的内分泌功能，因此可用于治疗或预防无排卵和不孕症。
• Assembled catalyst of palladium and non-cross-linked amphiphilic polymer ligand for the efficient heterogeneous Heck reaction
  作者：Yoichi M.A Yamada、Koji Takeda、Hideyo Takahashi、Shiro Ikegami

  DOI：10.1016/j.tet.2004.02.068

  日期：2004.4

  The efficient heterogeneous Heck reaction was achieved by a new networked and supramolecular catalyst PdAS-V (1b). Employing of PdAS-V in 5.0X10(-5) mol equiv. efficiently progressed the heterogeneous Heck reaction of a series of aryl iodides with acrylates. styrenes and acrylic acid. PdAS-V was successfully recycled five times without any decrease in its activity, and showed good stability in toluene and water, and hence the Heck reaction was efficiently performed in both reaction media. The use of 8.0X10(-7) mol equiv. of PdAS-V resulted in the coupling product in 92% yield with the turnover number (TON) and the turnover frequency (TOF) of PdAS-V reached up to 1,150,000 and 12,000, respectively. The efficient synthesis of resveratrol was achieved via the PdAS-V-promoted Heck reaction. (C) 2004 Elsevier Ltd. All rights reserved.
• NOVEL COMPOUNDS
  申请人：Astra Pharmaceuticals Limited

  公开号：EP0996621A1

  公开（公告）日：2000-05-03
• TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS
  申请人：AstraZeneca AB

  公开号：EP0996621B1

  公开（公告）日：2003-10-01